Aldara, Zartra(imiquimod)
Aldara, Imiquimod, Zyclara (imiquimod) is a small molecule pharmaceutical. Imiquimod was first approved as Aldara on 1997-02-27. It is used to treat actinic keratosis, basal cell carcinoma, and condylomata acuminata in the USA. It has been approved in Europe to treat actinic keratosis, basal cell neoplasms, condylomata acuminata, and keratosis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Imiquimod, Zyclara (discontinued: Aldara, Imiquimod)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Imiquimod
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZYCLARA | Bausch Health Companies | N-022483 RX | 2010-03-25 | 2 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imiquimod | ANDA | 2025-01-31 |
| imiquimod 5% / levocetirizine dihydrochloride 1% / niacinamide 2% | unapproved drug other | 2019-04-23 |
| imiquimod 5% / levocetirizine dihydrochloride 1% / tretinoin 0.05% | unapproved drug other | 2019-04-23 |
| imiquimod 5% / niacinamide 4% | unapproved drug other | 2019-05-06 |
| imiquimod 5% / salicylic acid 30% / tretinoin 0.1% | unapproved drug other | 2019-05-06 |
| imiquimod 5% / tretinoin 0.025% | unapproved drug other | 2019-05-06 |
| zyclara | New Drug Application | 2024-10-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| basal cell carcinoma | — | D002280 | — |
| actinic keratosis | — | D055623 | L57.0 |
| condylomata acuminata | EFO_0007147 | D003218 | A63.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Imiquimod, Zyclara, Bausch | |||
| 10918635 | 2030-04-30 | U-172, U-1455 | |
| 11202752 | 2030-04-30 | U-172, U-1455 | |
| 8222270 | 2029-12-11 | U-68 | |
| 8236816 | 2029-12-11 | U-68 | |
| 8299109 | 2029-12-11 | U-68 | |
| 10238644 | 2029-12-11 | U-68 | |
| 11318130 | 2029-12-11 | U-68 | |
| 8598196 | 2029-08-18 | U-172, U-1455 | |
| 10238645 | 2029-08-18 | U-172, U-1455 | |
| Imiquimod, Aldara, Bausch | |||
| 7696159 | 2024-04-01 | DP | U-1047, U-1048 |
HCPCS
No data
Clinical
Clinical Trials
190 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Actinic keratosis | D055623 | — | L57.0 | — | 1 | — | — | — | 1 |
| Keratosis | D007642 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | — | — | — | — | 1 | 1 |
| Lymphoma | D008223 | — | C85.9 | — | — | — | — | 1 | 1 |
| T-cell lymphoma | D016399 | — | — | — | — | — | — | 1 | 1 |
| T-cell lymphoma peripheral | D016411 | — | — | — | — | — | — | 1 | 1 |
| Mycosis fungoides | D009182 | — | C84.0 | — | — | — | — | 1 | 1 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Imiquimod |
| INN | imiquimod |
| Description | Imiquimod is an imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis. It has a role as an antineoplastic agent and an interferon inducer. |
| Classification | Small molecule |
| Drug class | immunomodulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)Cn1cnc2c(N)nc3ccccc3c21 |
Identifiers
| PDB | — |
| CAS-ID | 99011-02-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1282 |
| ChEBI ID | 36704 |
| PubChem CID | 57469 |
| DrugBank | DB00724 |
| UNII ID | P1QW714R7M (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Imiquimod
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 16,257 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,435 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use